MDNA - Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy | Benzinga
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") ((NASDAQ, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the Company will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy to be held from October 1 - 4, 2023, in Toronto, Canada.
Poster Title: Synergistically Engaging a ?-Selective IL-2 Agonist with PD1/PDL-1 Blockade in a Bifunctional Superkine, MDNA223.
Poster number: A005
Poster session: October 2nd, 2023 from 4.45 PM ET – 7.00 PM ET
The Company's Management will also participate in the ...